Rheumatoid Arthritis Treatment Market Growth Analysis, Share, Demand by Regions, Types and Analysis of Key Players- Research Forecasts to 2028

𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 released a new market study on 2022-2028 Rheumatoid Arthritis Treatment Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The global research report delivers an in-depth watch on leading competitors with strategic analysis, small and macro business trends and eventualities, valuation analysis and a holistic summary within the forecast amount. Its knowledge and in-depth reports specializing in primary and secondary drivers, market share, leading segments, and geographical analysis. Further, key players, major collaborations, merger & acquisitions of trending innovation and business policies reviewed within the report. The report contains basic, secondary and advanced data referring to international standing and trend, size, share, growth, trends analysis, section, and forecasts.

Request Here For PDF Brochure : https://www.coherentmarketinsights.com/insight/request-pdf/166

Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Rheumatoid can affect any joint, small joints in hand and feet tend to be affected the most. Treatments are available for rheumatoid arthritis help in relieving symptoms and improve the joint function. RA treatment usually involves the integration of patient education, exercise, medications, and surgery (occasionally).

The rheumatoid arthritis treatment market can be analyzed based on the drug type.

By Drug Type

‣Biological drugs

•Monoclonal antibodies

‣Non-Biologicals

•Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Corticosteroids
•Analgesics
•Disease-modifying anti-rheumatic drugs (DMARDs)
➡IL-6 inhibitors
➡TNF inhibitors

Major Players are: Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

NSAIDs and corticosteroids are also first-line fast-acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA for reducing inflammation, and pain. Corticosteroid medications can be given orally to reduce inflammation and restore joint mobility and function. The global rheumatoid arthritis treatment industry is expected to be driven considerably in the near future by DMARDs that form second line slow-acting therapeutic drugs. The longer therapeutic regimen with these drugs increases the cost of therapy and also promotes remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second-line drug for RA and hence, occupies a major share in the respective segment of the global rheumatoid arthritis treatment market.

FDA approved biologic drugs include rituximab (Rituxan, MabThera), abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), anakinra (Kineret), infliximab (Remicade), golimumab (Simponi), and tocilizumab (Actemra). Besides these approved drugs, biosimilars in the pipeline would fuel the rheumatoid arthritis treatment market growth in the near future.

Key statistics pertaining to the global rheumatoid arthritis treatment market:

➡Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patients.
➡Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
Most common in the age group of 30-60 years
➡The global prevalence varies in the range of 0.3% to 1% (World Health Organization)
➡The average annual cost of treatment may go up to the US $20,000 (RheumatoidArthritis.org)
➡According to the Arthritis Foundation, people with RA lose more workdays compared to those affected by any other medical condition
➡According to a Harvard University study published in the Journal of Global Health (2017), the prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries

Have a look on Sample Version of Report: https://www.coherentmarketinsights.com/insight/request-sample/166

A plethora of research work to develop effective treatment therapies in the global rheumatoid arthritis treatment market

The development of newer therapies is projected to fuel the growth of the rheumatoid arthritis treatment market in developed nations. The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO-ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015). Some of the products in the pipeline include:

Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)

Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)

More of such developments by the market players will be a significant contributor towards the growth of the global rheumatoid arthritis treatment industry.

Key Developments

Major players in the market are focused on gaining product approvals to expand their product portfolio. For instance, in August 2019, AbbVie, a biopharmaceutical company, received the U.S. approval for RINVOQ (upadacitinib), an oral JAK Inhibitor for the treatment of moderate to severe rheumatoid arthritis.

Major institutes and universities are increasing research and development for the development of novel therapies and technologies for the treatment of rheumatoid arthritis. For instance, in August 2019, researchers from the Kaohsiung Medical University, in the paper 'Next-Generation Sequencing Profiles of the Methylome and Transcriptome in Peripheral Blood Mononuclear Cells of Rheumatoid Arthritis' published in the journal MDPI Journal of Clinical Medicine, revealed a map to the peripheral blood mononuclear cells methylome and found that rheumatoid arthritis genetically associated genes and their interacting targets probably demonstrate differential methylation and differential expression than non-rheumatoid arthritis genetically associated genes.

Moreover, in August 2019, a team of researchers from the University of Groningen and the University of Exeter Medical School suggested that Gal-9, a pleiotropic immunomodulatory protein probably promotes immunopathology in rheumatoid arthritis through its stimulatory effect on granulocytes.

How Will The Rheumatoid Arthritis Treatment Market Report Be Beneficial?

This report will be a valuable assessment for new startups who wish to enter the Rheumatoid Arthritis Treatment Market, as it will not just provide the current market trends but also predict the future trends. You will get a look at the customised market segments according to geographical regions, country or even different combinations of manufacturers in the market.

Direct Purchase This Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/166

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:

Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

This release was published on openPR.